Example: Heart Attack

Search clinical trials for: Gefitinib

Total 281 results

NCT03122717

Active, not recruiting

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Conditions: Non-Small Cell Lung Cancer
NCT03333343

Recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Conditions: EGFR-mutant Non-small Cell Lung Cancer
NCT04248829

Recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Conditions: Non-Small Cell Lung Cancer
NCT03944772

Recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Conditions: Non-Small Cell Lung Cancer
NCT03866499

Recruiting

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Conditions: NSCLC
NCT02088112

Completed

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Conditions: Carcinoma, Non-Small-Cell Lung
NCT02411448

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Conditions: Metastatic Non-Small Cell Lung Cancer
NCT02296125

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Conditions: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
NCT02856893

Active, not recruiting

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

Conditions: NSCLC
NCT01982955

Active, not recruiting

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Conditions: Non-small Cell Lung Cancer
NCT03040973

Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.

Conditions: Advanced Solid Tumors Which Are cMET-dependent
NCT02893332

Terminated

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)

Conditions: Stage IV EGFR Mutated Non-Small Cell Lung Cancer
NCT04642547

Recruiting

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma, Molecular Targeted Therapy
NCT04390984

Recruiting

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Conditions: NSCLC
NCT01556191

Completed

Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

Conditions: Stage IV Lung Cancer
NCT03292133

Recruiting

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Conditions: Lung Cancer
NCT03239015

Recruiting

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

Conditions: Rare Tumor, Refractory Tumor
NCT00317772

Completed

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Conditions: Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
NCT01610336

Completed

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Conditions: Non-small Cell Lung Cancer
NCT00052208

Completed

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
NCT04575415

Recruiting

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Conditions: NSCLC
NCT01544179

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Conditions: Non-Small Cell Lung Cancer
NCT03758287

Recruiting

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Conditions: Non-small Cell Lung Cancer
NCT03267654

Recruiting

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Conditions: Non-small-cell Lung Cancer
NCT03457337

Recruiting

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Conditions: Advanced NSCLC With EGFR Mutation